JP2022512658A5 - - Google Patents
Info
- Publication number
- JP2022512658A5 JP2022512658A5 JP2021519735A JP2021519735A JP2022512658A5 JP 2022512658 A5 JP2022512658 A5 JP 2022512658A5 JP 2021519735 A JP2021519735 A JP 2021519735A JP 2021519735 A JP2021519735 A JP 2021519735A JP 2022512658 A5 JP2022512658 A5 JP 2022512658A5
- Authority
- JP
- Japan
- Prior art keywords
- manipulated
- diabetes
- platelets
- therapeutic agent
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743857P | 2018-10-10 | 2018-10-10 | |
| US62/743,857 | 2018-10-10 | ||
| PCT/US2019/055524 WO2020077037A1 (en) | 2018-10-10 | 2019-10-10 | Pd-l1 presenting platelets reverse new-onset type 1 diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512658A JP2022512658A (ja) | 2022-02-07 |
| JP2022512658A5 true JP2022512658A5 (enExample) | 2024-02-22 |
Family
ID=70165144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519735A Pending JP2022512658A (ja) | 2018-10-10 | 2019-10-10 | Ｐｄ－ｌ１提示血小板は、新たに発症する１型糖尿病を逆転させる |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210353679A1 (enExample) |
| EP (1) | EP3863650A4 (enExample) |
| JP (1) | JP2022512658A (enExample) |
| CN (1) | CN113164523A (enExample) |
| CA (1) | CA3115778A1 (enExample) |
| WO (1) | WO2020077037A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113694204A (zh) * | 2021-08-26 | 2021-11-26 | 南方医科大学南方医院 | 一种治疗骨髓炎的组合物及其应用 |
| CN114984219B (zh) * | 2022-03-29 | 2023-06-27 | 浙江大学 | Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途 |
| CN116159149B (zh) * | 2023-02-27 | 2024-11-15 | 上海中医药大学 | 一种基于血小板的免疫连接器的制备方法及应用 |
| CN118599772A (zh) * | 2024-06-12 | 2024-09-06 | 深圳市第三人民医院(深圳市肝病研究所) | 工程化免疫细胞、包含其的药物组合物及制备方法和应用 |
| CN119662531A (zh) * | 2024-12-19 | 2025-03-21 | 中山大学·深圳 | 一种工程化血小板及其制备方法与其在1型糖尿病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3250682A4 (en) * | 2015-01-26 | 2018-08-01 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| KR20180033537A (ko) * | 2015-07-21 | 2018-04-03 | 더 칠드런스 메디칼 센터 코포레이션 | Pd-l1 발현 조혈 줄기 세포 및 용도 |
| US10729730B2 (en) * | 2016-08-29 | 2020-08-04 | Hackensack University Medical Center | Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans |
| KR102557336B1 (ko) * | 2016-09-13 | 2023-07-18 | 노쓰 캐롤라이나 스테이트 유니버시티 | 혈소판 조성물 및 치료제의 전달 방법 |
-
2019
- 2019-10-10 CN CN201980080274.7A patent/CN113164523A/zh active Pending
- 2019-10-10 WO PCT/US2019/055524 patent/WO2020077037A1/en not_active Ceased
- 2019-10-10 JP JP2021519735A patent/JP2022512658A/ja active Pending
- 2019-10-10 US US17/284,087 patent/US20210353679A1/en not_active Abandoned
- 2019-10-10 CA CA3115778A patent/CA3115778A1/en active Pending
- 2019-10-10 EP EP19871609.4A patent/EP3863650A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ross et al. | Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation | |
| ES3036762T3 (en) | A modulatable switch for selection of donor modified cells | |
| CA3090548C (en) | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | |
| CN110637083A (zh) | 细胞及其使用和制备方法 | |
| JP7671125B2 (ja) | 免疫除去療法 | |
| US20220002671A1 (en) | T Cells with Improved Mitochondrial Function | |
| Kang et al. | Antigen-specific TCR-T cells for acute myeloid leukemia: state of the art and challenges | |
| Gao et al. | Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies | |
| Jaiswal et al. | CTLA4Ig primed donor lymphocyte infusion: a novel approach to immunotherapy after haploidentical transplantation for advanced leukemia | |
| Castagna et al. | Feasibility and efficacy of CD45RA+ depleted donor lymphocytes infusion after haploidentical transplantation with post-transplantation cyclophosphamide in patients with hematological malignancies | |
| US20210353679A1 (en) | Pd-l1 presenting platelets reverse new-onset type 1 diabetes | |
| JP2024177252A (ja) | カルボジイミドで処理された寛容化ワクチンによる移植寛容誘導 | |
| Limongello et al. | Novel immune cell-based therapies to eradicate high-risk acute myeloid leukemia | |
| WO2023228093A1 (en) | Cd19 car nk cells for use in methods of treating cancer | |
| Rajabi et al. | Primary progressive multiple sclerosis: new therapeutic approaches | |
| Chen et al. | Enhancing the efficacy of tumor vaccines based on immune evasion mechanisms | |
| Gong et al. | Alternative transplantation with post-transplantation cyclophosphamide in aplastic anemia: a retrospective report from the BMF-WG of Hunan Province, China | |
| JP2023522213A5 (enExample) | ||
| Maffini et al. | The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia | |
| Castagna et al. | Re-discovering NK cell allo-reactivity in the therapy of solid tumors | |
| EP3880216B1 (en) | Methods for treating cancer with manufactured t cells | |
| JP2025063190A (ja) | リンホトキシンアルファ遮断剤によりターゲットされた制御性ｔ細胞及びその使用 | |
| Berglund et al. | Stable mixed donor–donor chimerism after double cord blood transplantation | |
| Wu et al. | Comparative study of Bu/Cy/ATG and Flu/Cy/ATG conditioning regimens for unrelated donor hematopoietic stem cell transplantation in severe aplastic anemia | |
| Wang et al. | The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission |